The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Autoantibody Signatures in Prostate Cancer
Abstract
BACKGROUND: New biomarkers, such as autoantibody signatures, may improve the early detection of prostate cancer. METHODS: With a phage-display library derived from prostate-cancer tissue, we developed and used phage protein microarrays to analyze serum samples from 119 patients with prostate cancer and 138 controls, with the samples equally divided into training and validation sets. A phage-peptide detector that was constructed from the training set was evaluated on an independent validation set of 128 serum samples (60 from patients with prostate cancer and 68 from controls). RESULTS: A 22-phage-peptide detector had 88.2 percent specificity (95 percent confidence interval, 0.78 to 0.95) and 81.6 percent sensitivity (95 percent confidence interval, 0.70 to 0.90) in discriminating between the group with prostate cancer and the control group. This panel of peptides performed better than did prostate-specific antigen (PSA) in distinguishing between the group with prostate cancer and the control group (area under the curve for the autoantibody signature, 0.93; 95 percent confidence interval, 0.88 to 0.97; area under the curve for PSA, 0.80; 95 percent confidence interval, 0.71 to 0.88). Logistic-regression analysis revealed that the phage-peptide panel provided additional discriminative power over PSA (P<0.001). Among the 22 phage peptides used as a detector, 4 were derived from in-frame, named coding sequences. The remaining phage peptides were generated from untranslated sequences. CONCLUSIONS: Autoantibodies against peptides derived from prostate-cancer tissue could be used as the basis for a screening test for prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Self-citationGene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Self-citationThompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Self-citationHuman neoplasms elicit multiple specific immune responses in the autologous host.
Sahin, U., Türeci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., & Pfreundschuh, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11810 · Cited by 1,078
Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang‐Rodriguez, J., Moskaluk, C. A., Frierson, H. F., & Hampton, G. M. (2001) · PubMed · Cited by 856
A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
Stockert, E., Jäger, E., Chen, Y.-T., Scanlan, M. J., Gout, I., Karbach, J., Arand, M., Knuth, A., & Old, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1349 · Cited by 698
α-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer
Rubin, M. A. (2002) · JAMA · doi:10.1001/jama.287.13.1662 · Cited by 644
Self-citation
Cited by
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Sawyers, C. L. (2008) · Nature · doi:10.1038/nature06913 · Cited by 983
Mining the plasma proteome for cancer biomarkers
Hanash, S. M., Pitteri, S. J., & Faca, V. M. (2008) · Nature · doi:10.1038/nature06916 · Cited by 891
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies
Kulasingam, V., & Diamandis, E. P. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1187 · Cited by 771
Multiplexed protein measurement: technologies and applications of protein and antibody arrays
Kingsmore, S. F. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2006 · Cited by 715
Innate Immune Recognition of Cancer
Woo, S.-R., Corrales, L., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 571
Human body fluid proteome analysis
Hu, S., Loo, J. A., & Wong, D. T. (2006) · PROTEOMICS · doi:10.1002/pmic.200600284 · Cited by 533
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
Laumont, C. M., Banville, A. C., Gilardi, M., Hollern, D. P., & Nelson, B. H. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00466-1 · Cited by 524
Immune resistance orchestrated by the tumor microenvironment
Gajewski, T. F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., & Harlin, H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00442.x · Cited by 437
Autoantigen discovery with a synthetic human peptidome
Larman, H. B., Zhao, Z., Laserson, U., Li, M. Z., Ciccia, A., Gakidis, M. A. M., Church, G. M., Kesari, S., LeProust, E. M., Solimini, N. L., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1856 · Cited by 348
Fong, L., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8954 · Cited by 323
Serum autoantibodies as biomarkers for early cancer detection
Tan, H. T., Low, J., Lim, S. G., & Chung, M. C. M. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07396.x · Cited by 315
The peripheral-blood transcriptome: new insights into disease and risk assessment
Mohr, S., & Liew, C.-C. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.003 · Cited by 295
Zaenker, P., Gray, E. S., & Ziman, M. R. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.01.017 · Cited by 267
Display technologies: Application for the discovery of drug and gene delivery agents☆
SERGEEVA, A., KOLONIN, M., MOLLDREM, J., PASQUALINI, R., & ARAP, W. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.018 · Cited by 266
Immune Suppression in the Tumor Microenvironment
Gajewski, T. F., Meng, Y., & Harlin, H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199193.29048.56 · Cited by 265
Simple Sugars to Complex Disease—Mucin-Type O-Glycans in Cancer
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2014.11.002 · Cited by 260
Biomarkers of postoperative delirium and cognitive dysfunction
Androsova, G., Krause, R., Winterer, G., & Schneider, R. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00112 · Cited by 257
2D nanomaterials based electrochemical biosensors for cancer diagnosis
Wang, L., Xiong, Q., Xiao, F., & Duan, H. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.06.011 · Cited by 255
Proteomics in Clinical Trials and Practice
Azad, N. S., Rasool, N., Annunziata, C. M., Minasian, L., Whiteley, G., & Kohn, E. C. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r600008-mcp200 · Cited by 85
Metadata
- Authors
- Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., Mehra, R., Montie, J. E., Pienta, K. J., Sanda, M. G., Kantoff, P. W., Rubin, M. A., Wei, J. T., Ghosh, D., & Chinnaiyan, A. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-09-22
- Volume
- 353
- Issue
- 12
- Pages
- 1224-1235
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2041181510
- Cited by
- 582
- References
- 25
- FWCI
- 42.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.